Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Based on both the observational and
2020-11-23

Based on both the observational and theoretical data generated in this study, it appears that the mechanism(s) underlying lower IFM CPT1 activity is complex. Modeling enzyme activity versus alterations in catalytic efficiency (Fig. 3A) suggests that the observed age-associated changes in Km and Vmax
-
The immune control of CMV replication in vivo is
2020-11-23

The immune control of CMV replication in vivo is primarily driven by the T-cell-mediated response, a characteristic that has been proposed as a tool to individualize and therefore to optimize antiviral treatment [6], [7], and it has been associated with spontaneous clearance of CMV viraemia in patie
-
Introduction Human cytomegalovirus CMV is a herpesvirus whic
2020-11-23

Introduction Human cytomegalovirus (CMV) is a herpesvirus which has a ubiquitous and worldwide distribution, and is the most frequent cause of congenital infection (Kenneson and Cannon, 2007). The prevalence is around 0.5–1% of all live births and is the leading cause of sensorineural hearing loss
-
br Experimental Procedures br Author Contributions H G
2020-11-23

Experimental Procedures Author Contributions H.G. and X.-Y.F. conceived and designed the project. H.G., D.V.D., and X.L. performed most of the experiments and analyzed the data. L.X. helped on Mettl8 KO ESC, RIP, and translational study. Y.S. performed FACS analysis. Y.W. helped with cardiomyo
-
To develop novel EPAC inhibitors Zhou and co
2020-11-20

To develop novel EPAC inhibitors, Zhou and co-workers optimized the HTS hit as the chemical lead. After modifications of the substituents on the phenyl ring or C6-position of compound , compound () was identified to be the more potent compound in this series with an IC value of 4.0µM (EPAC2). Dock
-
The synthetic routes to the substrates based on the
2020-11-20

The synthetic routes to the substrates based on the 2,3-dihydroxynaphthalene and 6,7-dibromo-2,3-dihydroxynaphthalene cores are depicted in Scheme 3. A Michael-type glycosylation of 2,3-dihydroxynaphthalene 16a gave the acetylated sugar 17a which was deprotected giving the required β-glucosidase sub
-
We should also note that oxygen pressure of Krebs solution
2020-11-20

We should also note that oxygen pressure of Krebs solution bubbled with 95% O2+5% CO2 as we used in our study is reported to around 400 mmHg in several studies [48], [49], which is higher than normal arterial O2 pressure (80–100 mmHg). Although superoxide generation at elevated O2 tensions are noted
-
Anaesthetized mice of one eNOS KO
2020-11-20

Anaesthetized mice of one eNOS-KO strain showed a paradoxical decrease in blood pressure (BP) in response to i.p. administration of the NOS-inhibitor L-NA suggesting a role for non-endothelial isoforms of NOS in maintaining BP [1]. Alternatively, diminution in the activity of the renin-angiotensin s
-
As with all meta analysis this study
2020-11-20

As with all meta-analysis, this study certainly has some limitations. First, our results were derived from unadjusted analyses due to lack of raw data, and lack of further adjusted analyses for age, gender and co-morbidity conditions may impact the reliability of our findings [63]. Second, obvious h
-
br Author contribution br Acknowledgements We want to thank
2020-11-20

Author contribution Acknowledgements We want to thank Dr. Manuel Rodriguez, Dr. Ch. Blattner, Dr. Jorge Moscat, Dr. Erwin Knecht and Dr. Peter Tontonoz for materials. This work has been supported by grants from the Spanish Ministry of Education and ScienceSAF2011-27442 and a grant from General
-
2 hydroxyglutarate receptor The component E of PDHc
2020-11-20

The component E1 of PDHc (PDHc-E1) catalyzes the first step of multistep processes, using thiamine diphosphate (ThDP) and Mg2+ as cofactors.15, 16 Especially, this PDHc-E1 catalyzed process is a rate limiting step among multistep processes. Accordingly, the PDHc should be inactive by inhibiting the
-
The synthesis of compounds a and b are
2020-11-20

The synthesis of compounds 7a and 7b are outlined in Scheme 2. Compound 5 was obtained by di-tert-butyl pyrocarbonate protection of PRT-060318 4a. Then, compounds 6a and 6b were obtained by amination of the fluoride with a morpholino and dimethylamine, respectively. Target compounds 7a and 7b were
-
Long stretches of ssDNA have also
2020-11-20

Long stretches of ssDNA have also been observed in rad53-1 mutant Adaptaquin under replication stress using EM images (Sogo et al., 2002). Deletion of EXO1, a 5′-to-3′ exonuclease, can suppress the generation of ssDNA detected in rad53-1 mutant cells (Cotta-Ramusino et al., 2005). It was thus propos
-
We demonstrated that cells expressing less DHODH were
2020-11-20

We demonstrated that Isorhamnetin mg expressing less DHODH were less sensitive to DHODH inhibitors regardless of their oncogenic status. Based on the proliferation speed of cells, Kant et al. (1989), showed that slow-growing squamous cell carcinoma was more sensitive to BQR than fast-growing murine
-
The aim of this study was to
2020-11-19

The aim of this study was to evaluate the role of aberrant methylation of promoter regions of tumor suppressor genes in the clonal evolution from MGUS to MM. Thus, we analyzed in MGUS, SMM, and symptomatic MM patients, the methylation status of 4 genes—p15, p16, p53, and DAPK—whose promoter hyperme
16615 records 784/1108 page Previous Next First page 上5页 781782783784785 下5页 Last page